Loading...
INZY logo

Inozyme Pharma, Inc.NasdaqGS:INZY Stock Report

Market Cap US$259.7m
Share Price
n/a
1Y-10.9%
7D0%
1D0.3%
Portfolio Value
​
View

Inozyme Pharma, Inc.

NasdaqGS:INZY Stock Report

Market Cap: US$259.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Inozyme Pharma (INZY) Stock Overview

A clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. More details

INZY fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months compared to the US market

Has less than 1 year of cash runway

Earnings are forecast to decline by an average of 12.3% per year for the next 3 years

+ 1 more risk

INZY Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Inozyme Pharma, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Inozyme Pharma
Historical stock prices
Current Share PriceUS$4.00
52 Week HighUS$6.24
52 Week LowUS$0.72
Beta2.29
1 Month Change0.50%
3 Month Change387.09%
1 Year Change-10.91%
3 Year Change-21.26%
5 Year Changen/a
Change since IPO-77.20%

Recent News & Updates

Recent updates

Analysis Article • Nov 17

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Aug 03

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Jul 30

Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion

Summary Inozyme Pharma, Inc. interim data from the phase 1 SEAPORT-1 study, using INZ-701 for the treatment of patients with end-stage kidney disease with hemodialysis with calciphylaxis, expected Q4 of 2024. Fast Track Designation given by the FDA for the use of INZ-701 for the treatment of patients with ABCC6 Deficiency. Meeting with FDA to discuss potential of initiating a pivotal late-stage study using INZ-701 for the treatment of pediatric patients with ABCC6 Deficiency, expected end of 2024. Company had $166.2 million in cash as of March 31st of 2024; Enough cash on hand to fund its operations into Q4 of 2025. Read the full article on Seeking Alpha
Analysis Article • Apr 11

Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Mar 08

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward

Summary 48-week results from the phase 1/2 studies, using INZ-701 for the treatment of patients with ENPP1 Deficiency and ABCC6 Deficiency, expected in Q1 2024. Results from the phase 3 ENERGY-3 study, using INZ-701 for the treatment of patients with ENPP1 Deficiency, expected in mid-2025. An expansion opportunity exists for this company, which would be the advancement of INZ-701 for calciphylaxis that occurs in patients with end-stage kidney disease receiving hemodialysis. Initiation of phase 1 SEAPORT-1 study, using INZ-701 for calciphylaxis that occurs in patients with end-stage kidney disease receiving hemodialysis expected in 1st half 2024; Interim data Q4 of 2024. Read the full article on Seeking Alpha
Seeking Alpha • Aug 15

Inozyme Pharma GAAP EPS of -$0.38

Inozyme Pharma press release (NASDAQ:INZY): Q2 GAAP EPS of -$0.38. Cash, cash equivalents, and investments were $151.5M as of June 30, 2022. Based on its current plans, the company expects that its cash, cash equivalents, and investments as of June 30, 2022, together with the $25M available under the first tranche of its debt facility, will enable the company to fund its cash flow requirements into the second quarter of 2024.
Seeking Alpha • Jul 19

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Data from a handful of patients in the phase 1 portion of a phase 1/2 trial showed that Inozyme Pharma's (NASDAQ:INZY) INZ-701 led to positive biomarker, safety, and pharmacokinetic results in adults with ABCC6 Deficiency. All three adults showed rapid and significant increases in levels of pyrophosphate (PPi), a calcification inhibitor, after receiving the drug at a dose of 0.2 mg/kg. The company said in preclinical studies, PPi was predictive biomarker of therapeutic benefit. There were no serious adverse events reported. A grade 1 event was reported, though it was not related to INZ-701. Following review by a data safety monitoring board, InoZyme (INZY) plans to begin dosing in the next 0.6 mg/kg cohort this quarter and report topline data from Phase 1/2  trial in Q1 2023. Read about Inozyme's (INZY) recent partnership with the Rady Children’s Institute for Genomic Medicine.
Analysis Article • Jul 12

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Apr 06

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Dec 22

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 08

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 22

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 06

We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

INZYUS BiotechsUS Market
7D0%5.1%-2.7%
1Y-10.9%36.7%18.6%

Return vs Industry: INZY matched the US Biotechs industry which returned -10.8% over the past year.

Return vs Market: INZY underperformed the US Market which returned 13.9% over the past year.

Price Volatility

Is INZY's price volatile compared to industry and market?
INZY volatility
INZY Average Weekly Movement53.9%
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: INZY's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: INZY's weekly volatility has increased from 28% to 54% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201567Doug Trecowww.inozyme.com

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company’s lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway.

Inozyme Pharma, Inc. Fundamentals Summary

How do Inozyme Pharma's earnings and revenue compare to its market cap?
INZY fundamental statistics
Market capUS$259.66m
Earnings (TTM)-US$106.72m
Revenue (TTM)n/a
0.0x
P/S Ratio
-2.4x
P/E Ratio

Is INZY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INZY income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$106.72m
Earnings-US$106.72m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.64
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio145.6%

How did INZY perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/03 00:19
End of Day Share Price 2025/06/30 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Inozyme Pharma, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WhiteH.C. Wainwright & Co.
Joseph StringerNeedham & Company
Dae Gon HaStifel, Equities Research